Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present)

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• c-Met (hepatocyte growth factor receptor) is a transmembrane receptor tyrosine kinase.
• Aberrant c-Met/HGF signaling is linked to aggressive cancer phenotypes, advanced disease, and poor prognosis.
• c-Met is an emerging target for cancer chemotherapy.

Purpose of the Study:

• To review signaling pathways of c-Met.
• To discuss c-Met crystal structures and ligand binding modes.
• To update on c-Met inhibitors developed since 2014, including clinical development and future prospects.

Main Methods:

• Literature review of signaling pathways.
• Analysis of published crystal structures and binding modes.
• Summary of inhibitor design, synthesis, SAR, and clinical trials.

Main Results:

• c-Met signaling pathways are implicated in aggressive cancers.
• Crystal structures reveal ligand binding mechanisms.
• Numerous c-Met inhibitors have been developed, with several in clinical trials.

Conclusions:

• c-Met is a validated therapeutic target in oncology.
• Ongoing development of c-Met inhibitors shows promise for cancer treatment.
• Future research directions focus on optimizing inhibitor efficacy and clinical application.